The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Van K. Morris
Consulting or Advisory Role - Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
Bert O'Neil
Employment - Lilly
Honoraria - AstraZeneca
 
John A. Bridgewater
Honoraria - Merck Serono; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen; Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
Janet Graham
Honoraria - Bayer; Bristol-Myers Squibb; Merck Serono; nucana
Consulting or Advisory Role - Merck KGaA
Travel, Accommodations, Expenses - nucana
 
Eileen E. Parkes
Research Funding - STipe Therapeutics (Inst)
 
Mark P. Saunders
Honoraria - Merck Serono; SERVIER
Travel, Accommodations, Expenses - SERVIER
 
Elspeth Asken
Employment - Redx Pharma
Stock and Other Ownership Interests - Redx Pharma
 
Louise Goodwin
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Evgen (Inst); Redx Pharma (Inst)
 
Caroline Phillips
Employment - Redx Pharma
Stock and Other Ownership Interests - Redx Pharma
 
Jane Robertson
Employment - Achilles Therapeutics; Redx Pharma
Stock and Other Ownership Interests - Achilles Therapeutics; Redx Pharma
 
Craig Tilston
Employment - Redx Pharma
Stock and Other Ownership Interests - GlaxoSmithKline; Redx Pharma
 
Simon Woodcock
Employment - Redx Pharma
Stock and Other Ownership Interests - Redx Pharma
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
(OPTIONAL) Uncompensated Relationships - Roche